Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05672667 · ClinicalTrials.gov registry record · Phase 1

A Pharmacokinetic Study of Intravenous and Intranasal Oxytocin in Healthy Subjects

A Phase 1 study of Healthy Volunteer Study, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
Phase 1
Development phase
25
Enrollment target
1
Study location

NCT05672667: Completed Phase 1 study of Healthy Volunteer Study, sponsored by Wake Forest University Health Sciences.

NCT05672667 is a Phase 1 study of Healthy Volunteer Study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 25 participants, below the 34-participant average among 9 other Healthy Volunteer Study trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05672667, a Phase 1 study of Healthy Volunteer Study, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
Phase 1
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

The main purpose of this study is to sample blood and model the plasma pharmacokinetics (PK) of a single dose of intravenous (IV) oxytocin and a single dose of intranasal (i.n.) oxytocin. This is an unblinded study of subjects, all of whom will receive an intravenous (IV) infusion and intranasal (i.n.) dose of oxytocin (a naturally occurring hormone that is made in the brain) with blood samples taken thereafter in order to create a formula to describe the concentrations of oxytocin in the blood over time (pharmacokinetics). In this study healthy volunteers and people are recruited for a two day study. Each study participant will have 2 IV catheters placed (one in each arm) for the day of IV oxytocin dosing and 1 IV catheter on the day of i.n. oxytocin dosing. After placement of the IV catheters, an infusion of oxytocin will be given over a 30 minute period. Blood samples will be taken after the infusion begins and several times during and after the infusion. The blood will be drawn through the IV catheter not used for the oxytocin infusion. For the intranasal oxytocin administration day, 1 IV catheter will be placed and several blood samples will be taken after administration.

Primary Outcome

Blood will be sampled at specified intervals during and after the infusion. Plasma will be separated, rapidly frozen, and later analyzed for oxytocin concentration

Conditions Studied

Interventions

  • DRUG intravenous oxytocin
  • DRUG intranasal oxytocin

Study Locations (1)

North Carolina

  • Wake Forest Baptist Health - Winston-Salem

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2023-02-27
Est. Completion 2023-11-01
Phase Phase 1
Wake Forest University Health Sciences

1,140 total trials

What the finished NCT05672667 record still lists

NCT05672667 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 34-participant average among 9 other Healthy Volunteer Study trials with a reported enrollment target (26% lower).

The record links to 1 condition, with Healthy Volunteer Study appearing as the primary indexed condition, and to 2 interventions - of which intravenous oxytocin is the first listed.

NCT05672667 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT05672667 about?

NCT05672667 is a clinical study titled "A Pharmacokinetic Study of Intravenous and Intranasal Oxytocin in Healthy Subjects". The main purpose of this study is to sample blood and model the plasma pharmacokinetics (PK) of a single dose of intravenous (IV) oxytocin and a single dose of intranasal (i.n.) oxytocin. This is an unblinded study of subjects, all of whom will receive an intravenous (IV) infusion and intranasal (i...

What is the current status of trial NCT05672667?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2023-02-27. Estimated completion is 2023-11-01.

What conditions does trial NCT05672667 study?

This clinical trial studies the following conditions: Healthy Volunteer Study.

What interventions are being tested in trial NCT05672667?

The interventions under investigation include: intravenous oxytocin (DRUG), intranasal oxytocin (DRUG).

Who is sponsoring clinical trial NCT05672667?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05672667 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteer Study

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05672667's enrollment target sits among peer trials

25 7th of 9 higher than 3 of 9 other Healthy Volunteer Study trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteer Study trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05672667, the US trial registry maintained by the National Library of Medicine. NCT05672667 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.